1. Home
  2. FIVN vs BEAM Comparison

FIVN vs BEAM Comparison

Compare FIVN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five9 Inc.

FIVN

Five9 Inc.

HOLD

Current Price

$32.90

Market Cap

2.2B

Sector

Technology

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$29.57

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIVN
BEAM
Founded
2001
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.6B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
FIVN
BEAM
Price
$32.90
$29.57
Analyst Decision
Buy
Buy
Analyst Count
18
12
Target Price
$26.06
$50.75
AVG Volume (30 Days)
3.4M
1.7M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
364.71
82.31
EPS
0.25
N/A
Revenue
$1,149,088,000.00
$24,000.00
Revenue This Year
$11.39
N/A
Revenue Next Year
$10.00
$33.77
P/E Ratio
$129.20
N/A
Revenue Growth
10.28
33.33
52 Week Low
$13.29
$16.03
52 Week High
$34.58
$38.26

Technical Indicators

Market Signals
Indicator
FIVN
BEAM
Relative Strength Index (RSI) 61.21 57.05
Support Level $17.59 $28.40
Resistance Level $34.58 $34.20
Average True Range (ATR) 2.01 1.34
MACD -0.10 0.47
Stochastic Oscillator 73.51 78.71

Price Performance

Historical Comparison
FIVN
BEAM

About FIVN Five9 Inc.

Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: